Dennis M. Nally
Known title: DirectorCIK: 0001685596
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Morgan Stanley Q3 earnings met but stock remains under pressure. Morgan Stanley reported strong third-quarter results, yet the stock has not shown a significant reaction. The firm also highlighted stable demand in aerospace and defense and issued a positive signal regarding SpaceX. These developments provide fundamental support, even as the stock trades near its 52-week low and faces technical resistance.
Transaction History
| COR | ▲ Buy | Grant | 113 | $35K | 7/31/2026 | View on chart |
| MS | ▲ Buy | Grant | 1,310 | $0 | 6/1/2026 | View on chart |
| MS | ▲ Buy | Grant | 345 | $72K | 6/1/2026 | View on chart |
| COR | ▲ Buy | Grant | 116 | $35K | 5/1/2026 | View on chart |
| COR | ▲ Buy | Grant | 557 | $200K | 3/5/2026 | View on chart |
| COR | ▲ Buy | Grant | 98 | $35K | 1/30/2026 | View on chart |
| COR | ▼ Sell | Gift | 1,173 | $0 | 12/17/2025 | View on chart |
| MS | ▲ Buy | Grant | 430 | $73K | 12/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 104 | $35K | 11/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 122 | $35K | 8/1/2025 | View on chart |
| MS | ▲ Buy | Grant | 2,155 | $0 | 6/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 121 | $35K | 5/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 789 | — | 3/6/2025 | View on chart |
| COR | ▲ Buy | Grant | 123 | $31K | 1/31/2025 | View on chart |
| COR | ▲ Buy | Grant | 134 | $31K | 11/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 128 | $31K | 8/1/2024 | View on chart |
| MS | ▲ Buy | Grant | 2,675 | $0 | 6/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 137 | $31K | 5/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 843 | — | 3/12/2024 | View on chart |
| COR | ▲ Buy | Option Exercise | 1,593 | — | 3/11/2024 | View on chart |
| COR | ▲ Buy | Grant | 132 | $31K | 2/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 167 | $31K | 11/1/2023 | View on chart |
| COR | ▲ Buy | Grant | 166 | $31K | 8/1/2023 | View on chart |
| MS | ▲ Buy | Grant | 3,168 | $0 | 6/1/2023 | View on chart |
| COR | ▲ Buy | Grant | 188 | $31K | 5/1/2023 | View on chart |
| COR | ▲ Buy | Grant | 1,334 | — | 3/9/2023 | View on chart |
| COR | ▲ Buy | Option Exercise | 2,012 | — | 3/5/2023 | View on chart |
| COR | ▲ Buy | Grant | 194 | $31K | 2/1/2023 | View on chart |
| COR | ▲ Buy | Grant | 200 | $31K | 11/1/2022 | View on chart |
| COR | ▲ Buy | Grant | 215 | $31K | 8/1/2022 | View on chart |
| MS | ▲ Buy | Grant | 2,945 | $0 | 6/1/2022 | View on chart |
| COR | ▲ Buy | Grant | 207 | — | 5/2/2022 | View on chart |
| COR | ▲ Buy | Grant | 227 | — | 2/1/2022 | View on chart |
| COR | ▲ Buy | Grant | 255 | $31K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.